CJC-1295 DAC is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Single dose increases plasma GH 2-10 fold for 6+ days and IGF-1 0.5-3 fold for 9-11 days in humans. Multiple clinical trials demonstrated sustained dose-dependent GH/IGF-1 elevation. Reached Phase II before discontinuation. CJC-1295 DAC is not fda-approved. development discontinued post-phase ii. wada banned. available as research peptide.
What Does the Research Say About CJC-1295 DAC?
Single dose increases plasma GH 2-10 fold for 6+ days and IGF-1 0.5-3 fold for 9-11 days in humans. Multiple clinical trials demonstrated sustained dose-dependent GH/IGF-1 elevation. Reached Phase II before discontinuation.
CJC-1295 DAC (CJC-1295 with Drug Affinity Complex) is a GHRH analog with extended half-life. Research interest has focused on its potential effects on sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis, improved body composition, increased muscle mass.
What Is the Evidence for CJC-1295 DAC's Mechanism?
Binds GHRH receptors on pituitary somatotrophs to stimulate GH synthesis and secretion. The DAC module covalently binds to endogenous albumin, extending the half-life to 6-8 days while maintaining receptor bioavailability. This creates sustained, elevated GH levels rather than the pulsatile release seen with CJC-1295 no DAC.
These pathways have been identified through in vitro studies, animal models, and where available, human trials.
Are There Human Clinical Trials for CJC-1295 DAC?
Single dose increases plasma GH 2-10 fold for 6+ days and IGF-1 0.5-3 fold for 9-11 days in humans. Multiple clinical trials demonstrated sustained dose-dependent GH/IGF-1 elevation. Reached Phase II before discontinuation.
The gap between preclinical promise and clinical validation remains the biggest challenge in peptide research. However, CJC-1295 DAC has shown encouraging results.
What Does the Safety Research Show?
Water retention, joint aches, fluid retention, mild headache. Sustained GH elevation may cause more pronounced side effects than pulsatile release versions. One subject death in Phase II trial was attributed to unrelated coronary artery disease.
CJC-1295 DAC is not fda-approved. development discontinued post-phase ii. wada banned. available as research peptide.
What Makes CJC-1295 DAC Unique in Research?
The only GHRH analog with extended half-life allowing once-weekly dosing — but this convenience comes at the cost of sustained supraphysiological GH levels that bypass natural feedback, which is why most researchers prefer the no-DAC version.
This differentiator is important because it means CJC-1295 DAC fills a role that other compounds in its class may not fully replicate.
Bottom Line on CJC-1295 DAC Research
The evidence base for CJC-1295 DAC is growing. Key research areas include sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis, improved body composition, increased muscle mass.
Stay current with PubMed searches for CJC-1295 DAC for the latest publications.
Complete Guide
CJC-1295 DAC : Benefits, Dosage, Side Effects & Research
Related Reading
- CJC-1295 DAC Dosage Guide
- CJC-1295 DAC Benefits
- CJC-1295 DAC Side Effects
- CJC-1295 DAC Stacking Guide
- CJC-1295 DAC Cycle Guide
- CJC-1295 Complete Guide
Calculate Your CJC-1295 DAC Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for CJC-1295 DAC.
Open Calculator →Research-Grade Sourcing
If you're going to research CJC-1295 DAC, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is CJC-1295 DAC?
CJC-1295 DAC (CJC-1295 with Drug Affinity Complex) is a GHRH analog with extended half-life. Synthetic GHRH analog with four amino acid substitutions conjugated to a drug affinity complex that binds endogenous albumin. It is researched for sustained GH elevation, elevated IGF-1 levels, enhanced protein synthesis, improved body composition, increased muscle mass.
What is the recommended CJC-1295 DAC dosage?
Common dosages: 1-2 mg per injection administered once or twice weekly via subcutaneous injection. Cycle length: 12-16 weeks. Half-life: 6-8 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of CJC-1295 DAC?
Water retention, joint aches, fluid retention, mild headache. Sustained GH elevation may cause more pronounced side effects than pulsatile release versions. One subject death in Phase II trial was attributed to unrelated coronary artery disease.
Is CJC-1295 DAC safe?
CJC-1295 DAC has shown a preliminary safety profile in research. Not FDA-approved. Development discontinued post-Phase II. WADA banned. Available as research peptide. All research should follow appropriate safety protocols.